Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Fixed-Sequence, Single-Center, Two-Period, Drug-Drug Interaction Trial in Healthy Adult Participants to Evaluate the Effect of Steady-State ECC0509 on the Pharmacokinetics of Metformin (MATE1/2-K Probe Substrate), Midazolam (CYP3A4 Probe Substrate), and Caffeine (CYP1A2 Probe Substrate)

NCT07873229 is registered in ClinicalTrials.gov with Eccogene as lead sponsor.

NCT NCT07873229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Fixed-Sequence, Single-Center, Two-Period, Drug-Drug Interaction Trial in Healthy Adult Participants to Evaluate the Effect of Steady-State ECC0509 on the Pharmacokinetics of Metformin (MATE1/2-K Probe Substrate), Midazolam (CYP3A4 Probe Substrate), and Caffeine (CYP1A2 Probe Substrate)
Lead sponsor
Eccogene
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
April 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteo arthritis, steatohepatitis, nonalcoholic